Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II adaptive dose-ranging study of BAF312 in relapsing-remitting multiple sclerosis
2008-008719-25Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of siponimod in relapsing-remitting multiple sclerosis (RRMS) (6 arms), sponsored by Novartis. Primary endpoint: Monthly number of combined unique active MRI lesions during 3 months of treatment. Started Feb 2009; status: completed.
02
Drugs
siponimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2008-008719-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008719-25.